endpoints.news is our new home on June 1. endpts.com will still work, but the front door is now https://endpoints.news

FDA+ channel feed

FDA ap­proves first ther­a­peu­tic video game

5 years ago

Jazz Phar­ma’s $1B bet pays off with ac­cel­er­at­ed lung can­cer ap­proval

5 years ago
R&D

FDA weighs post-pan­dem­ic chal­lenges at BIO meet­ing

5 years ago
Coronavirus

Apel­lis coun­ters Alex­ion’s cri­tique, clears up FDA ques­tions as block­buster de­ci­sion looms

5 years ago
R&D

As­traZeneca spin­off scores maid­en FDA ap­proval, where it will field Alex­ion com­pe­ti­tion and an im­mi­nent Roche ri­val

5 years ago
R&D
Pharma

Pe­ter Marks dish­es on Covid-19 vac­cine de­vel­op­ment at BIO

5 years ago
Coronavirus

FDA de­fends its over­sight of for­eign drugs amid Sen­ate, GAO crit­i­cism

6 years ago

FDA de­lays de­ci­sion on No­var­tis’ po­ten­tial block­buster MS drug, wip­ing away pri­or­i­ty re­view

6 years ago
R&D

Cana­da’s drug price re­forms de­layed to 2021

6 years ago

Stephen Hahn: FDA will make some changes amid Covid-19 per­ma­nent

6 years ago
Coronavirus

Roche nabs front­line OK for Avastin/Tecen­triq in com­mon liv­er can­cer, best­ing an old Bay­er drug

6 years ago
R&D

Ab­b­Vie wins an ap­proval in uter­ine fi­broid-as­so­ci­at­ed heavy bleed­ing. Are ri­vals My­ovant and Ob­sE­va far be­hind?

6 years ago
R&D

FDA ex­plains im­pact of Covid-19 on ap­pli­ca­tions, for­mal meet­ings

6 years ago
Coronavirus

GSK's asth­ma drug Nu­cala gets speedy re­view for rare blood dis­or­der

6 years ago

Bris­tol My­ers Squibb fi­nal­ly gets in the front­line NSCLC game dom­i­nat­ed by Mer­ck, adding a sec­ond Op­di­vo/Yer­voy-based op­tion

6 years ago
Pharma

Al­ny­lam nabs speedy re­view, set­ting up 3rd pos­si­ble ap­proval in 3 years

6 years ago
R&D

FDA ap­proves the first gener­ic for Amar­in's Vas­cepa — but is a fish oil price war im­mi­nent?

6 years ago
Pharma

Parkin­son's pa­tients no longer need to re­ly on a nee­dle for apo­mor­phine an­ti­dote for 'of­f' episodes af­ter new FDA ap­proval

6 years ago
Pharma

Once val­ued at $4B, an em­bat­tled Ako­rn — nurs­ing a mar­ket cap of rough­ly $37M — files for bank­rupt­cy

6 years ago
Pharma

As CEO bounces back from Covid-19, Apel­lis says FDA meet­ing clears path to file for an OK on Soliris ri­val

6 years ago
R&D

EMA ex­tends vir­tu­al-on­ly meet­ing pol­i­cy through Au­gust

6 years ago
Coronavirus

FDA, Ae­tion part­ner on re­al-world da­ta an­a­lyt­ics for Covid-19

6 years ago
Coronavirus

As­traZeneca, Mer­ck push block­buster fran­chise to an­oth­er key FDA ap­proval, rel­e­gat­ing a ri­val to sec­ond-fid­dle sta­tus

6 years ago
Pharma

Years af­ter Keytru­da, Roche's Tecen­triq monother­a­py wins first-line NSCLC ap­proval. So does it mat­ter?

6 years ago
R&D
First page Previous page 129130131132133134135 Next page Last page
A service from the Financial Times